Become a fan of Slashdot on Facebook

 



Forgot your password?
typodupeerror
×
The Almighty Buck Businesses Medicine

Goldman Sachs Asks: 'Is Curing Patients a Sustainable Business Model?' (cnbc.com) 443

Goldman Sachs analysts attempted to address a touchy subject for biotech companies, especially those involved in the pioneering "gene therapy" treatment: cures could be bad for business in the long run. "Is curing patients a sustainable business model?" analysts ask in an April 10 report entitled "The Genome Revolution." From a report: "The potential to deliver 'one shot cures' is one of the most attractive aspects of gene therapy, genetically-engineered cell therapy and gene editing. However, such treatments offer a very different outlook with regard to recurring revenue versus chronic therapies," analyst Salveen Richter wrote in the note to clients Tuesday. "While this proposition carries tremendous value for patients and society, it could represent a challenge for genome medicine developers looking for sustained cash flow."

Richter cited Gilead Sciences' treatments for hepatitis C, which achieved cure rates of more than 90 percent. The company's U.S. sales for these hepatitis C treatments peaked at $12.5 billion in 2015, but have been falling ever since. Goldman estimates the U.S. sales for these treatments will be less than $4 billion this year, according to a table in the report. "GILD is a case in point, where the success of its hepatitis C franchise has gradually exhausted the available pool of treatable patients," the analyst wrote.

This discussion has been archived. No new comments can be posted.

Goldman Sachs Asks: 'Is Curing Patients a Sustainable Business Model?'

Comments Filter:
  • by K. S. Kyosuke ( 729550 ) on Monday February 18, 2019 @06:35AM (#58138764)
    "Slashdot asks: Is posting fresh stories a sustainable business model?"
  • Well.. (Score:5, Insightful)

    by Z80a ( 971949 ) on Monday February 18, 2019 @06:35AM (#58138766)

    Time to blacklist anyone working at goldman sachs from getting any sort of cure.

    • Re:Well.. (Score:5, Insightful)

      by arglebargle_xiv ( 2212710 ) on Monday February 18, 2019 @06:41AM (#58138772)
      The great vampire squid wants to be able to jam its blood funnel into anything that smells like money for as long as possible, not just as a one-off while they're cured. So keeping patients non-cured (sick) for as long as possible is the optimal path for them.
      • by bdwoolman ( 561635 ) on Monday February 18, 2019 @10:27AM (#58139768) Homepage
        Drillem, Billum, Killem and Chillum. Seriously, there is a whole class of human endeavor that is not made better by the profit motive. Healthcare certainly belongs in it. It is something that should be pursued by practitioners and institutions to improve the public good not to get filthy rich. Charging large sums of money to prolong life is essentially extortion. Most developed societies recognize this by having long ago instituted single-payer systems. It is expensive, but demonstrably such a system vastly improves the society's productivity and quality of life from the bottom up -- a measurable plus economically. And, besides, it is just the decent way to run things.
    • Re:Well.. (Score:5, Interesting)

      by Anonymous Coward on Monday February 18, 2019 @06:42AM (#58138778)

      No, they're got a point. Of course it isn't a sustainable business model. But that's OK. As long as the business gets a good ROI over time time period it doesn't matter if the profits dry up eventually. All this means is if you're going to value a company over the longer term, you should probably take effects like this into account.

      • Re:Well.. (Score:5, Insightful)

        by Anonymous Coward on Monday February 18, 2019 @06:46AM (#58138786)

        Why cure them entirely though, when you can mostly-cure them and treat the remaining effects with a lifetime supply of patented drugs?

        There is a market failure to research complete and cost effective cures for diseases.

        Medical research should be entirely funded by the public, and all patents and treatments that result made available to the public for free.

        Obviously, this leads to a better system. Stop trying to defend the status quo.

        • by Z80a ( 971949 )

          Brazil has a quite interesting way to deal with it.
          Basically, there are those "generic medications" that are pretty much the same medications of the big pharma but named by the components instead of brands, and the drug store sellers will find the correct generic of x medication of you ask for it.

          • Re: (Score:2, Interesting)

            They are just freeloading on research done by others, while contributing nothing to the advancement of medical knowledge.

            • by Z80a ( 971949 )

              Keeping people alive generally yields in good results in research as you have more alive people thinking.

      • If I may point out, this trade-off of short-term benefit versus long-term profit is true for many forms of technological obsolescence. A final technological solution to a long-standing industry requirement is one of the reasons for patents: it provides a reward to the inventors of the technology, for a limited period, so that the technology will be published and be available to the world.

      • by Rob Y. ( 110975 )

        What exactly is the business model in question? It seems to me that it's exploiting the patent system for all it's worth. You develop a drug and then hold it over the heads of disease sufferers - charging extortionate prices until you no longer can. The difference between a cure and a cash cow in this model is the difference in time between when the pool of disease sufferers dries up and when the patent expires.

        It would seem to me that reducing the length (and extendability) of drug patents would render

    • Re:Well.. (Score:5, Interesting)

      by getuid() ( 1305889 ) on Monday February 18, 2019 @08:50AM (#58139210)

      No, it's actually about high time somebody asked this question.

      The devil is not not talking about it, but what you make
      of that information. If the answer is "no", and the commonly agreed upon consequence
      is that we stop curing, then that's a big problem.

      But if the answer is "no", and the consequence is that we need
      to work towards making medical care a non-profit social enterprise,
      then that's a totally different pair of shoes.

      In any case, whatever the answer and whichever way the debate
      about the consequences goes, it all begins with the answer.

      (If you don't want the debate to make a turn for the most inhumane,
      then I guess you better be part of it early on instead of getting
      busy grinding your pitchfork just yet...)

      • Then let's ask (Score:5, Interesting)

        by Okian Warrior ( 537106 ) on Monday February 18, 2019 @10:06AM (#58139642) Homepage Journal

        No, it's actually about high time somebody asked this question.

        I've recently been thinking about this a little in terms of game theory: Insurance companies see medical care as an expense and premiums as income. Patients see medical care as a benefit and insurance premiums as an expense. This has led to a system with a whole lot of problems, but the fundamental flaw is that the two sides have fundamentally conflicting goals.

        How can we rework this into a better system?

        The first thing we need to do is define the goal of the system, and "longer average lifespan" seems like the right goal. We can also add a quality of life rider by saying that anyone can check out if their life becomes unbearable, with lots of safeguards against coercion and suicidal depression and such. (I imagine a process similar to sex-change operations - the patient has to really want it over an extended time, and have psychiatrist buy-in.)

        With "longer average lifespan" as the goal, now how do we pay the doctors?

        One answer might be to assign to the *doctor* (primary care physician) a monthly fee per patient, regardless of that patient needing medical service. If patients could switch to a new doctor at any time and for any reason, doctors would then have incentive to a) provide the best medical care, b) compete with each other for quality of service, and c) keep their patients healthy, happy, and long-lived.

        This seems to work at the "primary care physician" level, but it isn't a good fit for specialist and above, hospital care and ER. The PCP should feel free to refer a patient to a specialist without incurring a drop in salary, and an ER doc should have incentive to save a patient's life without regard to payment.

        Also, medical research should be included, so that there's incentive to cure diseases instead of masking symptoms.

        Anyone good at game theory like to add to this model?

      • Re:Well.. (Score:5, Insightful)

        by crunchygranola ( 1954152 ) on Monday February 18, 2019 @10:26AM (#58139766)

        No, it's actually about high time somebody asked this question.

        It is indeed. And the answer is clear. Medicine and medical research must not be driven by market economics.

        That medicine emerged as a major profit making industry in the 20th Century was due to a transitional phase in science and health care, wherein most things could not be cured, but treatment was huge business opportunity.

        Some of the most dramatic improvements in U.S., and world, health in the 20th Century was in the development of vaccines which were one of the cheapest interventions also. But what gets little attention is that this was always a government and charitable foundation activity, not a business, and not profit making.

        Health care must be a service available to everyone, with government taking the lead role in supplying it. There is plenty of room for business in the delivery process, but profit must not be allowed to drive health care decisions. Period.

    • by jellomizer ( 103300 ) on Monday February 18, 2019 @08:56AM (#58139248)

      The real question is, if finding a cure is not a sustainable business model. What is wrong with your business model?
      My father gave me his old table saw it is from the 1950's it still works, The company that made the saw is still around, and they still make table saws. You would think if you made such a quality device that once everyone who has a table saw, you wouldn't be able to sell them anymore.
      However, there are new things such as new safety features (this 1950's table saw is a death trap even beyond the blade, there are exposed belts, an exposed motor that seems to be a good bump away from sucking in the power cord...) There as well smaller sizes, or larger sizes, the ability to get better angles, to keep the material straighter, or make it easier to replace the blade.

      A company who makes a cure for a disease will one make a lot of upfront money from people demanding the cure. Which they can reinvest into finding the next condition that needs to be cured. It will be a long time for all problems to be cured.

      In the meantime the general population who is now healthier will be working and expanding the economy even further.

    • This statement of what should be obvious is a great service. They are saying what we have suspected for quite some time. That the for profit biotech business model is very likely against the best interests of individuals and society in circumstances where there could be a cure for disease.

      Society and individuals have great interests in curing people at least cost. Biotechs clearly have the contrary interest of creating treatments that create dependency and not cures. Having this stated succinctly is the

    • Comment removed (Score:5, Insightful)

      by account_deleted ( 4530225 ) on Monday February 18, 2019 @01:50PM (#58140866)
      Comment removed based on user account deletion
    • Re:Well.. (Score:4, Informative)

      by BringsApples ( 3418089 ) on Monday February 18, 2019 @02:06PM (#58140960)
      Man, these guys at Goldman Sachs are really stuck between a rock and a hard place.

      On one hand, they have their investors to consider.
      But on the other hand, they have their investors to consider.
  • by Opportunist ( 166417 ) on Monday February 18, 2019 @06:45AM (#58138782)

    Curing something does not mean you won't sell the same cure to the same person again. Just because you cured HepC, hell, even curing AIDS in a person does not mean they can't get infected again and need your cure again.

    The number of diseases that grant lifetime immunity to it after you survived it once is fairly low.

    • by Z00L00K ( 682162 )

      There's also always a new disease around the corner, so even if you eradicate one there's always new ones coming.

    • Just because you cured HepC, hell, even curing AIDS in a person does not mean they can't get infected again and need your cure again.

      If there is a cure, then the rate of re-infection will decline, possibly to zero, as the cure is applied to the population. Nobody gets smallpox anymore.

      One of the problems with our current medical system is that there is no incentive to develop cheap reliable effective cures.

    • Yes it is directly too. There's no reason not to cure people even if it is permanent because there's no single injection that cures anyone of everything. To use your example, just because you cured HepC, doesn't mean the person won't be back for more when he gets HepB or AIDS.

      We can start about the poor struggling MIC's profitability once people stop lining up for cures.

  • It is ... (Score:5, Insightful)

    by Going_Digital ( 1485615 ) on Monday February 18, 2019 @06:51AM (#58138798)
    If your competitors can't. If you develop a treatment and your competitor has a cure then your business is flushed down the toilet while your competitor gets rich. So unless the biotech companies collude with each other there is always the risk that a competitor will produce a cure killing your business, so you had better get there first and kill their business instead.
    • by Anonymous Coward

      Also, if it ever comes out that you developed a cure and withheld it in the name of profit, your head will rightfully be attached to a pike, which probably won't be good for your sustainability.

    • Libertarian answer to this:

      "So unless the biotech companies collude with each other there is always the risk that a competitor will produce a cure killing your business, so you had better [Patent it first] first and kill [kill off the entire industry with lawyers]."

    • by orzetto ( 545509 )

      So unless the biotech companies collude with each other [...]

      I think I may have found a flaw in your train of thought.

    • They don't have to collude with eachother, they just have to use common sense in a profit driven game theory. Lets say hypothetically treatment earns the company 6b a year. The cure would generate 20b for 1 year, 1b for every year after that, but render every companies treatment setting effectively dead. Making the cure will cost 10b and take 6 years. On a straight foward way, it makes sense that curing, isn't worth it, while yes the company that makes the cure would be the most profitable, it still hurts t
      • by mark-t ( 151149 )

        The most profitable option is still to stick with the treatment and hope everyone else also see's the same thing.

        I trust you realize that this operation depends, rather critically, on the idea that everyone else, particularly your competitors, will see things exactly the same way.

        The so-called "most profitable" option is also the riskiest... hope might very well be one of the most important traits we have as a species that can keep us going when outlooks are bad, but it's quite certainly a pretty crappy c

        • and... if they don't, you still pocket or re-allocate the 10b you would have spent on developing a cure, collect your 6b a year for as long as it takes them to develop it. By the time they are making a profit from their cure, you are laughing your way to the bank in the 4 other treatment plans you've gotten yourself invovled in, laugh as you still are making 6x more profit per year than that sucker company that is slowly making cure money... the faster short game you've made leaves you a good chance to buy
    • by AmiMoJo ( 196126 )

      Thing is it costs a lot of money to develop these treatments, and if they know their competitors are producing a treatment for a particular condition they won't even want to risk throwing money at their own competing product. It's even worse when there is an established treatment already in the market.

      Basically the same reason that you don't have a choice of two different cable companies. High costs just to get to offer you the service, in a market that is already saturated.

    • This is precisely why patents are granted. Duh.
    • Not exactly. The profit seekers can choose not to invest in research for a cure. But most of the basic research is University or other public funded stuff. So a competitor with less funding may just be slower at putting together the pieces and doing the relevant trials.

      That buys you more time to sell treatments.

  • That's a question (Score:5, Insightful)

    by Artem S. Tashkinov ( 764309 ) on Monday February 18, 2019 @06:56AM (#58138810) Homepage

    Yes, bloody idiots.

    The longer the person lives the longer he might be a client of various medical/pharmaceutical companies because we're not getting younger and healthier with each passing day.

    • I think the point is, if someone is 50, and catches a horrible painful disease. Is it more profitable to give a treatment that will let him live till 80 with really expensive monthly treatments. Or a 1 time cure that will let him live till 90. With the treatment option, he'll still need to go to the doctor for other sicknesses etc... in the meantime, actually they will probably be more frequent and more expensive patients for the normal colds/flu's etc... as the underlying sickness and the side effects from
  • For someone from GS to ask such a question, I'm surprised they're still employed there.

    I anticipate that they sell the cure at a price that makes it sustainable, or change the model to one where it's like a license... shut it down, or somehow disable it if the income stream stops.

    And people wonder why healthcare in the US is so fucking expensive. It's because we don't have any real competition, and one of the primary reasons Obamacare was never going to work. Stop allowing hospitals and pharma hide their

    • by dyfet ( 154716 )

      Indeed, they can "license" the altered genes instead and demand payment for your continued use by living. I am rather disappointed in GS, surely they can be far more evil than even this was.

  • Comment removed (Score:5, Insightful)

    by account_deleted ( 4530225 ) on Monday February 18, 2019 @07:12AM (#58138852)
    Comment removed based on user account deletion
    • Are you under the delusion that European pharmaceutical companies don't make a profit?

      • by JustNiz ( 692889 )

        that just proves that US drug companies could survive even if they were legally moderated.

        • I'm not sure what you mean by "legally moderated". US companies have to follow laws. What kind of "legal moderation" is placed on European pharmaceutical companies which isn't placed on American ones? Or, more specifically, which existing European controls are you advocating be brought in for US companies?

        • Do you mean regulated? They are.
      • by Kiuas ( 1084567 ) on Monday February 18, 2019 @08:41AM (#58139168)

        Are you under the delusion that European pharmaceutical companies don't make a profit?

        No, and he didn't even imply that. The point is however, that the way medicines are bought here means that the prices of drugs are lower. The companies still make a profit off of them, but we spend overall less money on drugs, because of things like collective bargaining.

        Take something like insulin. The price of insulin in the US doubled from 2012 to 2016 [reuters.com], and it's not because the product itself has change or consumption has skyrocketed. Quoting the article:

        “It’s not that individuals are using more insulin or that new products are particularly innovative or provide immense benefits,” Jeannie Fuglesten Biniek, a senior researcher at HCCI and the report’s co-author said in a phone interview.

        “Use is pretty flat, and the price changes are occurring in both older and newer products. That surprised me. The exact same products are costing double,” she said.

        And one of the 3 main manufacturers of insulin is Novo Nordisk, a Danish pharmacompany. So yes, European pharma companies are raking in a lot of money thanks to in no small part the american medical system. Now keep in mind, this is not some new wonder drug, insulin has been around for decades at this point, the manufacturing process has been honed down and is extremely efficient. A study from 2017 [businessinsider.com] estimated the cost of production to be as follows:

        After analyzing expenses for ingredients, production, and delivery, among other things, the researchers contend that the price for a year's supply of human insulin could be $48 to $71 a person and between $78 and $133 for analog insulins, which are genetically altered forms that are known as rapid or long-acting treatments. Examples of analog insulins include Humalog, Lantus, and Novolog.

        Put another way, the study estimated the cost of production for a vial of human insulin is between $2.28 and $3.42, while the production cost for a vial of most analog insulins is between $3.69 and $6.16, according to the study in BMJ Global Health. Meanwhile, the median prices paid by more than two dozen countries for human insulin were 1.2 to 1.8 times greater than estimated prices. Median prices for other types of insulin were also higher: Lantus, which is sold by Sanofi (SNY), was 5.6 to 7.8 times higher; Humalog, which is sold by Eli Lilly (LLY), were at 2.7 to 3.7 times higher; and Novolog, a Novo Nordisk (NVO) treatment, was 2.6 to 3.5 times greater.

        Note: the siggested figures there are not the costs of manufacturing, they're suggested price-points at which the companies would still make a profit on the product. And the actual numbers are global medians. In the US, the average price for a year's supply is now around $5700 dollars a year (from the previous link). Depending on the type of insulin, that's a markup of anywhere from 100 % to around 640 %. On a life-saving chemical that people depend on daily. That's insane. This is only possible because even though there's competition in theory, the highly more privatized nature of the US pharma/medical sector has allowed for all the three major players to raise their costs in tandem, while simultaneously making no significant changes/improvements on the drug itself.

        The commercialized nature of the system means it doesn't optimize itself for cost-efficiency or availability, it optimizes for maximal profit. Insulin is cheap to make, so obviously the companies sell it for very cheap in countries with lower incomes or just a better regulated health care system. This

        • by c6gunner ( 950153 ) on Monday February 18, 2019 @09:44AM (#58139518) Homepage

          There's a lot of misinfo and half truths in there ... I'll address some of the bigger ones:

          1. Collective bargaining benefits exist in the US also. Insurance companies pay much lower prices than those cited, exactly because of their bargaining power. The costs you're discussing are costs outside of the insurance system, and as such aren't really comparable to anything in nations which control all sale/distribution.

          2. Insulin has changed significantly over the years, and the prices for newer products are therefore higher. The newest generation of insulin is far safer and more effective than the stuff being made back in the 1930s. If you want some of the older stuff you can get it way cheaper in many markets.

          3. Looking at solely the cost of production and then saying that "a 100% markup is insane" is just ridiculous. There are many other costs associated with these products, not the least of which are regulatory costs, and R&D. Pharmaceutical R&D in particular is insanely expensive. While the costs for R&D on insulin specifically may not be as high as some others, companies use profits from one product to offset general research costs, not just development costs of that one line.

          4. I don't think you understand how patents work. You don't get to hang on to a patent for longer just by making small changes. You can probably get a new patent for your changed product, but the old patent will still expire. Once it expires, others are free to copy your old product. The issue in the US is that, if you want to copy an older form of insulin for example, you still have to jump through the regularity hoops to get your product approved for sale by the FDA. You also still have the usual marketing costs to try and make people aware of your cheaper product, AND you'll probably have to work to convince doctors to actually prescribe your cheaper version rather than the better, more expensive product. All of that is going to raise your costs quite a bit higher than just those "production" costs you were talking about earlier. The easiest way to get more generics on the US market would be to get the FDA out of the way by lowering standards or automatically accepting generics which are approved in other markets ... but then you're potentially sacrificing safety for speed (see Thalidomide, for example).

          All that said, if you think that you can compete by making an older, cheaper form of insulin ... what's stopping you? Go fire up a Kickstarter to get some initial funding, get your business set up, and then maybe hit up some of the charitable foundations for funding. If you had a workable plan to bring low cost generic insulin to the US market (and actually succed in selling it) I'm sure you could get plenty of startup funding from, say, the Bill and Melinda Gates Foundation.

          I hear lots of people like you banging on about the immorality of making money selling medicine, yet none of you seem to be interested in actually doing something about it. The only "solution" you have seems to be price controls, which is wonderful because it allows you to act morally superior without having to actually do anything. Just get the government to fix things for you; that's always the best solution!

          • by Bert64 ( 520050 )

            I hear lots of people like you banging on about the immorality of making money selling medicine, yet none of you seem to be interested in actually doing something about it. The only "solution" you have seems to be price controls, which is wonderful because it allows you to act morally superior without having to actually do anything.

            The solution is not price controls, the solution is to separate research and manufacturing.
            Have research be non-profit, conducted by charities and governments with the results made available to all. Not only would you eliminate the likelihood of profit being chosen over the wellbeing of patients, but you could also increase collaboration as researchers would no longer be competing against each other and wouldn't have any incentive to keep their research secret.

            Pharmaceutical companies should purely be about

          • by Anonymous Coward on Monday February 18, 2019 @11:43AM (#58140220)

            50 year Type 1 diabetic here.

            > Insulin has changed significantly over the years

            The purity improved drastically since its discovery in 1921, which is how animal source insulins became safer and less likely to cause sensitivities, basically allergies, that reduced their effectiveness profoundly. The patent for insulin itself was made public domain by its inventor. The release of "human" insulin, and the patents for making it, were an effective attempt to get new patents, not to provide medical benefit from a natural chemical which cannot be patented. There seems to be no measurable medical benefit to the human insulin molecule over animal sources, and there are some reports of medical deficits with it.

            The folks at Novo are always *really excited* by the insulins. But the short acting human insulin only replaces the older regular insulin, and its speed of action is overwhelmed by the modern glucometer use and by the quick action of delivering insulin with an insulin pump. The longer acting human insulin based Lantus simply replaces NPH or UltraLente, older and cheaper ways to make insulin last longer. There is *zero* net benefit from the modern human insulins over the older and vastly cheaper animal based insulins. Using e. coli to make insulin doesn't actually improve it in any measurable way.

            > The newest generation of insulin is far safer and more effective than the stuff being made back in the 1930s.

            That is a false equivalency. Compared to the 1930's sure. Improvements in insulin effectively ceased in the 1970's with the last upgrade to "U-100" concentrations of insulin. The developments for insulin since then have been like the "new" and "improved" labels on detergent, or like marking farmer's market produce as "non-GMO". Very exciting and an excuse to charge more, but involving no useful change in the product and likely untrue.

            Yes, the "human" insulins were exciting. But using the human rather than the animal insulins has no demonstrable medical benefit, and costs roughly 10 times as much. Insulin is *grotesquely* expensive due to the captive market and the basically fraudulent "upgrades" over the last 30 years.. A classic example of drug companies continuing to blow smoke up our asses is seen at the "article" at https://www.adwdiabetes.com/ar... [adwdiabetes.com]. I've not seen such a nonsensical puff piece since Sarah Palin campaigned for Trump.

      • by AmiMoJo ( 196126 )

        Pharma companies make less profit in Europe, including the American ones selling drugs here. For example, in the UK most people use the tax-funded NHS, and relatively few have private healthcare that will pay for expensive treatments. So if they want to sell a drug to the UK market, they have to negotiate with the NHS and they don't pay commercial rates.

        It's still profitable so they still do it. Might as well make some money rather than nothing. It's far from perfect but we don't see the same price inflatio

    • There's still the problem that European health systems, too, need to rely on for-profit businesses to provide drugs and stuff, and they need to be sustainable, i.e. profitable, to survive.

      A problem that has no solution within the confinements of the world's existing economic operating system.

    • The main problem is looking at health care as a profit driven business in the first place. Take a look at Europe / Scandinavia for examples of much better models.

      If it were true that that alone makes it more likely to find cures then Europe/Scandinavia would be coming up with cures that Americans could then just benefit from.

      Whether it be a "non-profit" or for profit company there seems to be a problem in the economics and incentives of cures versus treatments. There is just going to be more money in treatments than there will be in cures. I think there is something more fundamental that needs to be recognized there that affects either type of business model. An

    • There's nothing different in Europe / Scandinavia. The only difference is where the profits come from, the sick person, or the taxes they paid. Healthcare is still a profit driven business, even if the person filling out the prescription and the person paying for the drugs is covered by socialised healthcare.

  • Many of us here probably know people who convinced that a cure for all cancers already exists, but somebody big (the government, pharma, maybe both) doesn't want it out because the revenue stream from current expensive treatments will dry up. This just feeds into their arguments that big business is against us all.
    • Curing cancer is a little different and would be highly profitable. You would wipe out all your competitors that also compete against you in other drug areas. Cancer is also something where curing it once will not prevent you from getting it again and again and again and keep needing a different customized cure. Also a cure from cancer could be sold at a truly staggering price and it would still be worth it so you manufacture far less of a complex drug substance at a MUCH higher price per unit.

    • by qbast ( 1265706 )
      Ask them how the hell vaccines exist then and watch half of them go non-verbal and the other half start ranting about autism and conspiracies to poison us all.
    • by Miser ( 36591 )

      I actually have said this before. Pick your $dreaded_disease and it would not surprise me in the slightest if 100% proof surfaced that $some_evil_company had the cure for ages, but stuffed in a safe somewhere in lieu of just putting people on maintenance. I'm not saying I believe this, but it wouldn't shock me if someone showed me proof that it were true.

      My other thought is though, as the saying goes, three people can keep a secret if two are dead. How could someone of good conscience keep a cure for say

  • You have to keep paying off everyone that comes up with a cure? That doesnt seem sustainable.

  • This is the inevitable logical conclusion of for-profit health care. I'm not at all surprised.

    The US health care system is fucking awful (unless you're in the 1%). We need single payer now.
    • by JustNiz ( 692889 )

      > We need single payer now.

      No, big health/pharma already owns the government, so any change would only be to their benefit, regardless of what you call it.

      We need the foxes out of the hen house first..

      • by DogDude ( 805747 )
        The first step is to get Big Insurance out of the picture. That is a massive drag on society that adds nothing.
  • by JustNiz ( 692889 ) on Monday February 18, 2019 @07:42AM (#58138938)

    The drug companies already avoid cures, as that would eliminate their customers.
    They just make drugs that temporarily suppress symptoms (and often introduce others) just so they have a repeat customer base.

  • New business model (Score:5, Interesting)

    by iTrawl ( 4142459 ) on Monday February 18, 2019 @07:46AM (#58138948)

    There are two choices, and they have their detractors:

    1. Socialism: We all pay for this and enjoy the benefits of a healthy society.
    2. Ferengi: Mortgage. Because the treatment works so well, it is also expensive, and the only way to finance it is by taking a lifetime loan. If you need a second treatment, better take a second mortgage then.

    • 2B we all pay for an inmate to get that treatment + the cost of locking them up. As under the law it's cruel and unusual Punishment to not have healthcare

  • They're looking at new advances in medicine the wrong way. These fantastic new cures rely on a model of customizing the cure for the patient. So, rather than selling a particular drug, these investors/manufacturers should look at it as selling Cure-O-Matic machines which when loaded with the patient's DNA and some parameters then produce customized drugs. Such machines will need consumables, reagents, spare parts, and programming. That's the new source of revenue.

  • No matter what your product, planning to sell the same thing forever doesn't work, you'll run out of customers or competitors will paste you. The key is to keep developing new products and always keeping a step ahead of competition.
  • Drugs are patented for 20 years, it means that in the ideal case where your competitor didn't find something better your "recurring revenue" is going to be severely cut down by cheap generics after your patent expire.
    If you develop a cure however, you are going to completely destroy your competition, and get a good backlog of already ill patients to treat. Sure, it won't last, but neither will your patent. So the ones who aren't getting rich are the ones who make generics, you get to keep all the profits.

  • Because there are a host of medical conditions out there that will ALWAYS require preventative/palliative care.

    Blowing out as much in the way of disease/etc as possible with actual CURES stops the medical apparatus from being overwhelmed. Especially by serious conditions that require extensive (and expensive), ongoing medical support.

    It allows us to "right size" our medical industry. Rather than building out this huge industry that has to stretch to cover ongoing care for every conceivable medical issue H

  • That this question is asked lays bare the fundamental question of health care. The fact is, care costs money so how does it get paid for? Either healthcare is a business or it is supported by the people for the people (taxes thru government).
    This question, as revolting as it is, simply puts in stark relief the reality of the choices.

  • Comment removed based on user account deletion
  • Maybe not. But then it shouldn't be a business, maybe ? Get it off the business and let the state handle it. It will save a huge amount of money for everyone in the long run. To say nothing of saving lives.
  • Remember that coworker that tries to keep everything secretive about their work to protect their job? Then the world comes along and changes without them, forcing them on the street because they were so focused on protecting what they have that they didn't invest time in learning anything new. This is literally how that sounds.

    The problem is that regardless of automation, there will always be something else pushing us forward, new skills to learn, more problems to solve. Curing illnesses would be great i

  • This is, in one quote, exactly the reason why it should be illegal for medicine to be for profit. Prioritizing profit over life is the very definition of evil.

  • This sounds like the exact plot for the movie Johnny Mnemonic [imdb.com]. The "black shakes" was affecting much of the population, due to excessive exposire to technology, and the "big pharma" / pharmacorp were keeping the cure a secret because "it was more profitable to treat the symptoms than to cure the patient"

    As I recall, it didn't end well for PharmaCorp.

  • In an unregulated market, competitors could compete directly on price and quality of care.
  • There is a reason that the big pharma companies are spending all their research money to develop drugs that relieve symptoms temporarily, but don't actually cure anything. Think statins, impotence pills for men, and various skin nostrums to improve your complexion. These are all big money-makers and none of them cure anything. Rather, they alleviate symptoms temporarily, and require the patient to continue buying them for the rest of his or her life to enjoy their benefits. Now, this is a good business

  • Why does the wealthiest nation in the entire world have one of the least effectual healthcare systems in the developed world? Because it can afford it!

    As long as companies have a vested interest in treating a chronic condition without curing it, we in the US are doomed to live with them. The longer term they are as chrnic illnesses, the better.

    I can't help wondering how much money and pain Jonas Salk saved the world. There were 20,000 to 57,000 cases of polio in the US each year until the vaccine was in
  • Sounds to me the problem isn't capitalism so much as it's lazy people (e.g. Bankers) who believe after they produce something they are entitled to sit idle and keep getting paid for doing nothing in return.

  • Look at the common cold: Billions each year to treat the symptoms, but if it was cured, Big Pharma might suffer horribly.

    Ditto for Caner, Diabetes, the Flu and Allergies.

    This then becomes a shining (sci-fi based) example of Cures for the Rich, and the rest for everyone else.

  • ... investment bankers a sustainable business model back in 2007?

  • Why do you think the pharmacy industry gives you all the sob stories wanting more money for "research into a cure" because they know if they CURE something, they are OUT of business.
  • how much money is enough?
    The principals in a biotech company made a couple billion $ and then ran out of patients? Boo-hoo.

    If you develop a cure for one disease, you may run out of patients who need that cure, but there are always other diseases that need to be cured. If you don't want to risk your money on the development of another cure, retire to your private island and let someone else do the work.

If mathematically you end up with the wrong answer, try multiplying by the page number.

Working...